Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P415: Dose escalation of adalimumab and related prognostic factors in patients with Crohn's disease treated with adalimumab maintenance therapy: A single-centre, five-year cohort studyECCO '18 Vienna
Year: 2018
Authors:

M. Nasuno*, H. Tanaka, K. Sugiyama, M. Miyakawa, S. Motoya

Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan

P416: Metabolite measurement for thiopurine therapy in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

E. Sánchez Rodríguez*, R. Ríos León, Á. Flores de Miguel, A. Guerrero García, A. Albillos Martínez, A. López Sanromán

Hospital Ramón y Cajal, Servicio Gastroenterología y Hepatología, Madrid, Spain

P417: Crohn disease recurrences: Nothing new under the sun?ECCO '18 Vienna
Year: 2018
Authors:

M. Giulii Capponi*, E. Rausa, M. Lotti, F. Bianco, G. Panyor, A. Indriolo, P. Ravelli, L. Campanati

Papa Giovanni XXIII Hospital, Bergamo, Italy

P418: Predictive factors of surgery in the course of Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

K. Agar*, M. Medhioub, S. Jardak, L. Hamzaoui, A. Khsiba, M.M. Azzouz

Med Taher Maamouri Hospital, GastroEnterology Department, Nabeul, Tunisia

P419: Frequency of inadequate response to anti-tumour necrosis factor therapy in patients with ulcerative colitis. Preliminary results from POLIBD studyECCO '18 Vienna
Year: 2018
Authors:

A. Pekala*, R. Filip

Kliniczny Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej, Rzeszów and Faculty of Medicine, University of Rzeszów, Poland, Department of Gastroenterology with IBD Unit, Rzeszow, Poland

P420: Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn’s disease and ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

C. Gheorghe1, P. Svoboda2, A. Dimitriu1*, B. Mateescu3, I. Kotzev4

1Fundeni Clinical Institute of Digestive Diseases and Liver Transplantation, Gastroenterology, Bucharest, Romania, 2University Hospital Ostrava, Ostrava, Czech Republic, 3Clinical Hospital Colentina, Bucharest, Romania, 4UMHAT Sveta Marina, Varna, Bulgaria

P421: SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with active mild-to-moderate ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

B. Misra1, J. Curran2, H. Herfarth3, K. Jagarlamudi4, C. Oneto5, B.R. Bhandari6, G. Wiener7, D. Kerman8, A. Moss9, R. Pomerantz10, J. Zhao10, P. Bernardo10, S. Simmons10, L. Diao10, E. O’Brien10, M. Henn10, M. Trucksis10*

1Borland-Groover Clinic, Jacksonville, USA, 2Community Clinical Research Network, Marlborough, USA, 3University of North Carolina School of Medicine, Chapel Hill, USA, 4PMG Research of Salisbury, Salisbury, USA, 5Concorde Medical Group PLLC, New York, USA, 6Delta Research Partners, Monroe, LA, United States, 7GW Research Inc., Chula Vista, CA, USA, 8University of Miami Hospital, Miami, FL, USA, 9Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA, 10Seres Therapeutics, Cambridge, MA, USA

P422: Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1ECCO '18 Vienna
Year: 2018
Authors:

E.V. Loftus1, B.E. Sands2, J.-F. Colombel3, I. Dotan4, J.M. Khalid5, D. Tudor6, P. Geransar7*

1Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, USA, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA, 3Gastroenterology, Mount Sinai Hospital, New York, USA, 4Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel, 5Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK, 6Takeda Pharmaceuticals International AG, Zurich, Switzerland, 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland

P423: Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCUECCO '18 Vienna
Year: 2018
Authors:

M. Chaparro1,2,3,4*, J.L. Cabriada5, M.J. Casanova1,2,4, D. Ceballos6, M. Esteve4,7, H. Fernández8, M. Barreiro-de Acosta9, V. García-Sánchez10,11, D. Ginard12, F. Gomollón4,13,14, R. Llorente Poyatos15, P. Nos4,16, S. Riestra17, M. Rivero18, P. Robledo19, C. Rodríguez Gutiérrez20, B. Sicilia21, E. Torrella22, F. Rodríguez-Artalejo23,24,25, J.P. Gisbert1,2,3,4, on behalf of the EpidemIBD group

1Hospital Universitario de La Princesa, Gastroenterology Unit, Madrid, Spain, 2Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain, 3Universidad Autónoma de Madrid, Madrid, Spain, 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, 5Hospital de Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain, 6Hospital Universitario de Gran Canaria Doctor Negrín, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain, 7Consorci Sanitari Terrassa, Gastroenterology Unit, Tarrasa, Spain, 8Hospital San Pedro, Gastroenterology Unit, Logroño, Spain, 9Hospital Clínico Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 10Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 11IMIBIC, Córdoba, Spain, 12Hospital Universitario Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain, 13Hospital Clínico Universitario Lozano Blesa, Gastroenterology Unit, Zaragoza, Spain, 14ISS Aragón, Zaragoza, Spain, 15Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain, 16Hospital Universitario y Politécnico de La Fe, Gastroenterology Unit, Valencia, Spain, 17Hospital Universitario Central de Asturias, Gastroenterology Unit, Oviedo, Spain, 18Hospital Universitario de Marqués de Valdecilla, Gastroenterology Unit, Santander, Spain, 19Hospital San Pedro de Alcántara, Gastroenterology Unit, Cáceres, Spain, 20Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain, 21Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain, 22Hospital General Universitario Morales Meseguer, Gastroenterology Unit, Murcia, Spain, 23Universidad Autónoma de Madrid, Preventive Medicine and Public Health, Madrid, Spain, 24IdiPAZ, Madrid, Spain, 25Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

P424: Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: Sub-analysis from TRUSTECCO '18 Vienna
Year: 2018
Authors:

T. Kucharzik1*, C. Maaser2, U. Helwig3, N. Börner4, J. Gronych5, A. Rössler5, S. Rath5, TRUST Study Group

1University Teaching Hospital Lüneburg, Department of Internal Medicine and Gastroenterology, Lüneburg, Germany, 2University Teaching Hospital Lüneburg, Ambulanzzentrum Gastroenterologie, Lüneburg, Germany, 3Gastroenterology Practice, Oldenburg, Germany, 4Gastroenterology Practice, Mainz, Germany, 5AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany

P425: Proactive measurement of infliximab trough levels vs. clinical management in inflammatory bowel disease: multicentre studyECCO '18 Vienna
Year: 2018
Authors:

A. Elosua González1*, D. Oyón Lara1, P. Sanz Segura2, M. Arroyo Villariño3, S. García López2, C. Rodríguez Gutiérrez1, Ó. Nantes Castillejo1

1Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 2Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, 3Hospital Clínico Universitario Lozano Blesa, Gastroenterology, Zaragoza, Spain

P426: Meta-analysis of endorectal advancement flap vs. ligation of the intersphincteric fistula tract for Crohn’s and cryptoglandular high perianal fistulasECCO '18 Vienna
Year: 2018
Authors:

M.E. Stellingwerf*, E.M. van Praag, W.A. Bemelman, C.J. Buskens

Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands

P427: Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)ECCO '18 Vienna
Year: 2018
Authors:

A. Walsh1*, P. Seeva1, C. Hinds2, V. Sexton3, O. Brain1, S. Keshav1, H. Uhlig1, J. Geddes3, G. Goodwin3, M. Peters4, G. Collins5, S. Travis1

1John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, UK, 2Big Data Institute, Oxford, UK, 3University of Oxford, Psychiatry Department, Oxford, UK, 4University of Oxford, Nuffield Department of Population Health, Oxford, UK, 5University of Oxford, Centre for Statistics in Medicine, Oxford, UK

P428: Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): Utility of and cost-saving associated with the use of a rapid assay for assessing drug levelECCO '18 Vienna
Year: 2018
Authors:

C. Rentsch1*, M. Sparrow2,3, M. Ward2,3, K. Taylor2,3, A. Friedman2,4, R. Luber2,3, H. Su2, R. Hopkins1, B. Head-on2, M. Dooley2,3, P. Gibson2,4

1Alfred Health, Pharmacy, Melbourne, Australia, 2Alfred Health, Gastroenterology, Melbourne, Australia, 3Monash University, Centre for the Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Melbourne, Australia, 4Monash University, Department of Medicine, Melbourne, Australia

P429: Robotic-assisted vs. laparoscopic proctectomy for inflammatory bowel disease: Results of the case-match comparison in single institutionECCO '18 Vienna
Year: 2018
Authors:

M.V. Marino1*, A. Glagoleva2

1Azienda Ospedaliera Villa Sofia-Cervello, Emergency and General Surgery, Palermo, Italy, 2P.L Shupyk National Medical Academy Of Postgraduate Education, Kyiv, Ukraine

P430: Distinct faecal bile acid profiles are associated with sustained remission following exclusive enteral nutrition (EEN) induction therapy in paediatric Crohn's diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Connors1*, R. Bandsma2, B. MacIntyre1, S. Whitehouse1, A. Noble1, M. Rashid1, A. Otley1, J. Van Limbergen1

1IWK Health Centre, Pediatric Gastroenterology and Nutrition, Halifax, Canada, 2Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada

P431: Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodologyECCO '18 Vienna
Year: 2018
Authors:

I. Detrez1*, E. Dreesen1, G. Van Assche2, S. Vermeire2, M. Ferrante2, A. Gils1

1KU Leuven, Leuven, Belgium, 2UZ Leuven, Leuven, Belgium

P432: Does medical acceleration improve long-term outcomes in ulcerative colitis patients who are in clinical remission but have endoscopic mucosal inflammation?ECCO '18 Vienna
Year: 2018
Authors:

J.Y. Chang*, J.H. Cheon, Y. Park, S.J. Park, T.-I. Kim, W.-H. Kim

Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea

P433: Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapyECCO '18 Vienna
Year: 2018
Authors:

R.W.M. Pauwels*, A.C. De Vries, C.J. Van der Woude

Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands

P434: Remission induction in corticosteroid naive children and adolescents with active ulcerative colitis by adsorptive leucocytapheresis after failure of first-line medications: Results from routine clinical practiceECCO '18 Vienna
Year: 2018
Authors:

T. Tanaka*, M. Akagi, H. Goishi, T. Iiboshi, T. Kajihara, T. Miura

Akitsu Prefectural Hospital, Hiroshima, Japan